Findings

What do systematic reviews say?

4 questions · 4 findings · 2 reviews · Musculoskeletal

No studies found 1 · 25%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 50%High 1 · 25%

ACR50% improvement criteria · patients with rheumatoid arthritis

Tocilizumab 8 mg/kg + MTX/DMARD leads to higher ACR50% improvement criteria compared with placebo + MTX/DMARD (high certainty).

1 finding from 1 review

Tocilizumab for rheumatoid arthritis 2010 · Cochrane Headline outcomes only
RR 3.17 [2.72, 3.67]
4 studies · 2063 participants
High

ACR50 American College of Rheumatology improvement criteria · participants with rheumatoid arthritis and with partial response to MTX

The intervention probably leads to higher ACR50 American College of Rheumatology improvement criteria (moderate certainty).

1 finding from 1 review

Etanercept for the treatment of rheumatoid arthritis 2013 · Cochrane Headline outcomes only
RR 11.69 [1.66, 82.47]
1 study · 89 participants
Moderate

ACR50 American College of Rheumatology 50% improvement criteria · participants with rheumatoid arthritis and with a partial response to DMARDs

The intervention probably leads to higher ACR50 American College of Rheumatology 50% improvement criteria (moderate certainty).

1 finding from 1 review

Etanercept for the treatment of rheumatoid arthritis 2013 · Cochrane Headline outcomes only
RR 1.96 [1.33, 2.89]
4 studies · 1198 participants
Moderate

Outcome: ACR50 ‐ American College of Rheumatology Improvement Criteria · participants with rheumatoid arthritis

The review found no eligible studies for this question.

1 finding from 1 review

Etanercept for the treatment of rheumatoid arthritis 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found